Qsemble Capital Management LP Takes Position in Avantor, Inc. (NYSE:AVTR)

Qsemble Capital Management LP purchased a new position in shares of Avantor, Inc. (NYSE:AVTR) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 32,013 shares of the company’s stock, valued at approximately $828,000.

Other institutional investors also recently bought and sold shares of the company. 1832 Asset Management L.P. raised its stake in shares of Avantor by 1,634.9% during the 2nd quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock worth $180,839,000 after buying an additional 8,038,451 shares during the period. Sound Shore Management Inc. CT acquired a new position in Avantor during the second quarter worth $76,412,000. Principal Financial Group Inc. lifted its holdings in Avantor by 146.5% during the third quarter. Principal Financial Group Inc. now owns 2,628,372 shares of the company’s stock valued at $67,996,000 after purchasing an additional 1,562,018 shares in the last quarter. Canada Pension Plan Investment Board grew its position in shares of Avantor by 6.8% in the second quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock valued at $486,059,000 after purchasing an additional 1,463,695 shares during the period. Finally, Boston Partners increased its stake in shares of Avantor by 2.2% during the first quarter. Boston Partners now owns 28,561,802 shares of the company’s stock worth $729,298,000 after purchasing an additional 624,369 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Stock Down 0.4 %

AVTR stock opened at $21.01 on Wednesday. The firm has a market cap of $14.30 billion, a PE ratio of 45.67, a PEG ratio of 2.52 and a beta of 1.35. Avantor, Inc. has a one year low of $19.59 and a one year high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The firm’s 50 day moving average price is $23.65 and its 200-day moving average price is $23.79.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AVTR shares. Barclays decreased their price target on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. UBS Group lowered their price target on Avantor from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Tuesday, October 8th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price objective on shares of Avantor in a research note on Thursday, September 26th. Wells Fargo & Company lowered their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, October 28th. Finally, Robert W. Baird reduced their target price on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.57.

Insider Buying and Selling at Avantor

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of Avantor stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the sale, the chief accounting officer now directly owns 29,544 shares in the company, valued at $740,372.64. This trade represents a 10.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.30% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.